Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-04-15 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2025-04-15 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2025-04-15 English
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Earnings Release Classification · 99% confidence The document is explicitly titled 'Press Release' and details clinical trial updates (Phase 2 data for amlitelimab, plans for lunsekimig and itepekimab) and future study readouts (H2 2025, 2026). It includes quotes from R&D leadership and contact information for Media and Investor Relations. This format strongly indicates an official announcement of recent company developments, specifically related to research and pipeline progress, rather than a comprehensive statutory filing like a 10-K or a formal quarterly report (IR). Since it is a press release announcing scientific/pipeline progress, it is best classified as an Investor Presentation (IP) if it were a deck, but as a general announcement of corporate news, it fits best under the 'Regulatory Filings' (RNS) category as a general announcement, or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results. Given the focus is purely on R&D pipeline updates and not summarizing overall financial performance for a period, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback, although 'IP' (Investor Presentation) is sometimes used for detailed pipeline updates presented to investors. However, since this is a press release format, RNS is safer than IP, which usually implies a slide deck. It is not an ER because it lacks summary financial figures. It is not an MDA because it is a press release, not a management discussion section. I will classify it as RNS as a general corporate announcement. Q2 2025
2025-04-15 English
Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO
Earnings Release Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and details clinical trial updates (Phase II and Phase III plans) for several drug candidates (amlitélimab, lunsekimig, itépekimab) related to respiratory diseases. It includes quotes from management, scientific details, and contact information for press and investor relations. This format is characteristic of an initial announcement of significant business or scientific progress, often preceding a formal regulatory filing or a detailed report. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a formal Audit Report (AR). Since it is a press release announcing scientific/business progress and results, it most closely aligns with an Earnings Release (ER) if it were tied to financial results, but here it is focused purely on R&D pipeline updates. Given the options, this type of announcement, which is a formal communication of material, non-financial operational news, often falls under the general category of a Regulatory Filing (RNS) if a more specific category like ER or MDA doesn't fit perfectly. However, because it is a detailed update on clinical progress and pipeline strategy, it shares characteristics with an Investor Presentation (IP) or Management Discussion & Analysis (MDA). Since it is a press release format summarizing R&D progress and future plans, and not a formal presentation deck or a detailed management report section, the best fit among the provided codes for a significant, non-financial operational update released via press release is often RNS, or potentially ER if it were framed around quarterly performance, which it is not. Given the focus on pipeline advancement and clinical data dissemination, and lacking a specific 'R&D Update' code, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of corporate communication that isn't a standard financial report or presentation. Q2 2025
2025-04-15 French
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It references a press release dated April 8, 2025, attached as Exhibit 99.1, but does not contain detailed financial statements or substantive financial data itself. The document length is short (1349 characters), and it primarily serves as a regulatory filing to announce the press release publication. According to the rules, such filings that announce or attach other reports without containing the report itself should be classified as Regulatory Filings (RNS).
2025-04-10 English
Sanofi - Combined General Meeting of April 30, 2025 - Availability of Preparatory documents
AGM Information Classification · 98% confidence The document explicitly announces the details for a 'Combined General Meeting' scheduled for April 30, 2025. It discusses the publication of the 'notice of meeting' (*avis de réunion* and *avis de convocation*) and informs shareholders where the 'preparatory documents' for this meeting are available. This content directly relates to the logistics, agenda, and materials surrounding an Annual General Meeting (AGM). Therefore, the classification should be AGM Information (AGM-R). The document is an announcement about the AGM materials, not the meeting presentation itself, but AGM-R is the most specific category for AGM-related materials announcements.
2025-04-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.